Vieworks Co (100120) Fair Value & Analysis
Healthcare · KR · Market cap 201B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Fair value updated Jul 20, 2026, revised from 41,633 KRW to 43,404 KRW (+4.3%) since Jul 7, 2026. Share price +9.1% over the past month.
A solid business, screening 68% undervalued on our models.
What matters now
- The price is below even our cautious bear case (26,505 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (26,505 KRW to 54,255 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 17,526 KRW – 41,468 KRW · fair‑value band 26,505 KRW – 54,255 KRW · the 25,900 KRW price screens below the 43,404 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Vieworks Co (100120) currently trades at 25,900 KRW, while our model-based Fair Value estimate is 43,404 KRW, implying the stock looks roughly 67.6% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Vieworks Co generated revenue of 243B KRW at a net margin of 12.0%. Revenue grew 6.9% year over year. It earns a return on equity of 11.8%. Net debt stands at 37.4B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 26,505 KRW (bear case) to 54,255 KRW (bull case); at 25,900 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 48% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at 68%, 100120 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (44,269 KRW) versus Asset-Based (19,434 KRW). Highest evidence: Growth DCF (80).
Notify me when 100120 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 52
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vieworks Co., Ltd. develops, manufactures, and sells imaging systems and solutions. The company offers X-ray detectors and image processing technologies for general radiography system, dental and surgical C-arm systems, radiography and fluoroscopy system, veterinary radiography system, industrial inspection instrument, and other applications.
Full company description
Vieworks Co., Ltd. develops, manufactures, and sells imaging systems and solutions. The company offers X-ray detectors and image processing technologies for general radiography system, dental and surgical C-arm systems, radiography and fluoroscopy system, veterinary radiography system, industrial inspection instrument, and other applications. It also provides industrial cameras; and bio imaging systems comprising in vivo imaging systems under the VISQUE brand. The company was formerly known as Raysis Co., Ltd. and changed its name to Vieworks Co., Ltd. in November 2006. Vieworks Co., Ltd. was founded in 1999 and is headquartered in Anyang-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Vieworks Co reported revenue of 239B KRW in FY2025 versus 193B KRW in FY2021, a compound +5.5%/yr. Reported net income was 22.0B KRW in FY2025, compounding −10.0%/yr from FY2021.
Watch 100120: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Vieworks Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vieworks Co (100120) overvalued or undervalued?
What is the fair value of 100120?
What is the quality score of 100120?
What is the revenue of Vieworks Co (100120)?
What is the net profit margin of 100120?
Does Vieworks Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Vieworks Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.